MB
Therapeutic Areas
Eli Lilly Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Type 2 Diabetes | Approved |
| Tirzepatide (Zepbound) | Obesity | Approved |
| Donanemab | Alzheimer's Disease | Phase 3 |
| Mirikizumab | Ulcerative Colitis | Phase 3 |
| Lebrikizumab | Atopic Dermatitis | Phase 3 |
| Orforglipron | Type 2 Diabetes | Phase 3 |
| Pirtobrutinib | B-cell Malignancies | Phase 3 |
| Retifanlimab | Various Cancers | Phase 2/3 |
Leadership Team at Eli Lilly
DA
David A. Ricks
Chairman and Chief Executive Officer
AA
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
DM
Daniel M. Skovronsky
Chief Scientific and Medical Officer, President of Lilly Research Laboratories
AE
Anne E. White
Executive Vice President and President of Lilly International
PJ
Patrik Jonsson
Executive Vice President, President of Lilly USA
IY
Ilya Yuffa
Executive Vice President and President of Lilly Manufacturing Operations
CS
Christi Shaw
Executive Vice President and President of Lilly Oncology
MM
Mike Mason
Executive Vice President and President of Lilly Diabetes
RG
Ruth Gimmi
Executive Vice President, Chief Information and Digital Officer